Nonalcoholic Steatohepatitis Therapeutics Market
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
liver disease in Western countries. Thus, there is an urgent need<br />
for effective treatment options for these diseases. The need for<br />
treatment is expected to propel the growth of NASH<br />
therapeutics in coming years.<br />
The NASH market is segmented based on drug type which<br />
includes potential phase III candidates such as Obeticholic acid<br />
(OCA), Aramchol, Saroglitazar and Elafibranor. Moreover, the<br />
report provides a list of the candidates in Phase I and Phase II<br />
clinical trials. Based on the drug type, Elafibranor is expected to<br />
account for a major share of this market followed by Obeticholic<br />
Acid (OCA) market and the market for Elafibranor is expected<br />
to grow at the highest CAGR.<br />
The market overview section of the report demonstrates major<br />
market dynamics such as drivers, restraints, and opportunities<br />
that influence the current and future status of the industry. The<br />
market overview section includes epidemiology of <strong>Nonalcoholic</strong><br />
steatohepatitis (NASH) by region, to provide a thorough<br />
analysis of the overall addressable global market for the NASH<br />
therapeutics. Moreover, the report provides qualitative<br />
information about diagnosis and treatment of NASH.